In the current stock analysis, the investor holds shares in Michael Dupke Aachen Biotech PAION AG (ISIN: DE000A0B65S3, WKN: A0B65S, Ticker Symbol: PA8, NASDAQ OTC Symbol: PAIOF) of the journal Der Axner.
As announced over the weekend, PAION may mark another important milestone for the anesthetic Remimasolam (Bifavo). On Monday, Biotech Small-Cap responded to the news with a great price. However, the recently announced capital increase will then turn into a negative factor.
Accordingly, PAION has received approval from the European Commission for Bifavo in Practical Fainting for Adults. The company is preparing to launch in the second half of 2021 Bifavo and two additional products indicated for use in intensive care medicine in hospitals in selected European markets.
One week ago, PAION announced that a capital increase would be implemented. It plans to issue about five million shares at a price of just 4 1.54 per share. After the announcement of corporate action, PAION stock plummeted as the issue price became clearer than the previous price.
The market has not rewarded the numerous improvements made by FIFA in recent months. Today’s price hike is very likely to be resold. The declared capital increase is a short-term burden on PAION stock.
Interested newcomers are now waiting to calm down the chart, but Michael Dupke of “Der Axner” says PAION shares will remain enjoyable for a long time. (Analysis from March 29, 2021)
See also information on disclosure obligations in the event of conflicts of interest within the meaning of the Directive 2014/57 / EU and related EU regulations. Under the following link.
Stock Markets PAION Stock:
Trading Stock Price PAION Stock:
2,13 EUR + 9,51% (29.03.2021, 09:09)
XETRA Stock Price PAION Stock:
1,935 EUR + 0.78% (26.03.2021, 17:36)
WKN PAION Share:
Tigger Logo Germany PAION Share:
Short Profile PAION AG:
PAION AG (ISIN: DE000A0B65S3, WKN: A0B65S, Tigger Symbol: PA8, NASDAQ OTC Symbol: PAIOF) is a listed specialty pharmaceutical company that manufactures innovative active ingredients for use in outpatient and hospital anesthesia, anesthesia and intensive care medicine. The purpose of post-marketing. The leading combination of PAION is Remimasolam, an intravenous, ultra-short-acting and easily controlled benzodiazepine anesthetic and anesthetic. Remimozolam has joined forces in several markets outside Europe. Remimosol is approved for brief anesthesia in the United States and China and for general anesthesia in Japan and South Korea.
PAION aims to be a leading specialist pharmaceutical company in the field of anesthesia and complex care medicine by bringing to market new products that benefit patients, physicians and health partners.
PAION is headquartered in Aachen and has another location in Cambridge (United Kingdom). (29.03.2021 / ac / a / nw)
Expression of conflicts of interest:
You can find interesting conflicts on the site of the creator / source of the analysis.